ML
FLXN

McAdam LLC’s Flexion Therapeutics, Inc. FLXN Stock Holding History

McAdam LLC’s Portfolio FLXN Stock Details FLXN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q4 		– Sell
-90
Closed -$2K – 688
2018
Q3 		$2K Hold
90
– – ﹤0.01% 547
2018
Q2 		$2K Hold
90
– – ﹤0.01% 519
2018
Q1 		$2K Buy
+90
New +$2.2K ﹤0.01% 587

Other funds holding FLXN

MVP
Miller Value Partners Sarasota, Florida $423M AUM 49.14% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
GGHC
Gilder Gagnon Howe & Co New York $9.69B AUM 55.7% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Wells Fargo
Wells Fargo San Francisco, California $617B AUM 30.33% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return
PAMU
Pictet Asset Management (UK) London, United Kingdom $91.8B AUM 47.77% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

McAdam LLC's FLXN Position: Q4 2018 in Review

McAdam LLC sold out of Flexion Therapeutics, Inc. (FLXN) in Q4 2018, closing a stake of 90 shares — an estimated $2K sold.

McAdam LLC first reported a position in FLXN in Q1 2018 and held it in 3 quarters. The position peaked at $2K in Q3 2018. 125 funds tracked by Wall St. Rank hold FLXN as of Q4 2018.

  • McAdam LLC reported no remaining Flexion Therapeutics, Inc. position as of Q4 2018 after selling out during the quarter.
  • McAdam LLC sold 90 Flexion Therapeutics, Inc. shares in Q4 2018, an estimated $2K.
  • McAdam LLC first reported a position in Flexion Therapeutics, Inc. in Q1 2018 and held it in 3 quarters.
  • McAdam LLC's Flexion Therapeutics, Inc. position peaked at $2K in Q3 2018.
  • 125 funds tracked by Wall St. Rank held Flexion Therapeutics, Inc. as of Q4 2018.

Based on McAdam LLC's 13F filing for Q4 2018, filed 30 Jan 2019.